Lifecare Innovations Private Limited

lifecareinnovations.com

Lifecare Innovations is a R&D intensive company specialised in controlled release pharmaceuticals employing an array of technologies of novel drug delivery systems. The first product is a Liposome mediated delivery of Amphotericin B to target fungal or leishmania cells. Lifecare Innovations received Technology Day 2004 National Award for Bio-technology in recognition of the indigenous development and production of life saving drug - FUNGISOME. The award function was presided by His Excellency the President of India Dr. A.P.J. Abdul Kalam. The award and the citation were presented by the Minister of Science Technology and Ocean Development Mr. Kapil Sibbal. Lifecare Innovations is engaged in the development of number of other controlled release drugs in collaboration with national institutions. These are under various stages of development. Predominant among these are a range of anti-fungals. To complement anti-fungal treatment, Lifecare Innovations has also launched Itraconazole capsules under the brand name FUNGITRACE

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

BIOMARIN ANNOUNCES ADVANCEMENTS IN FDA REVIEW OF ROCTAVIAN™ (VALOCTOCOGENE ROXAPARVOVEC) FOR ADULTS WITH SEVERE HEMOPHILIA A

BioMarin Pharmaceutical Inc. | November 24, 2022

news image

BioMarin Pharmaceutical Inc. announced advancements in the U.S. Food and Drug Administration review of the Biologics License Application of ROCTAVIAN™ for adults with severe hemophilia A. The Company was recently notified by the FDA that after further consideration, at this time, the Agency no longer plans to hold an advisory committee meeting to discuss the BLA for ROCTAVIAN that is currently under review. Previously, the FDA communicated to the Company that it did intend to hold an...

Read More

Business Insights

STALLERGENES GREER STRENGTHENS PRECISION MEDICINE APPROACH IN ALLERGEN IMMUNOTHERAPY WITH IMPERIAL COLLEGE LONDON RESEARCH COLLABORATION

Stallergenes Greer | January 17, 2022

news image

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine. This long-term research collaboration, which combines the long-standing expertise of Stallergenes Greer in AIT with the prestigious r...

Read More

Pharmacy Market

CSTONE AND LEGOCHEM BIOSCIENCES ENTER GLOBAL LICENSING AGREEMENT FOR NEW ANTIBODY DRUG CONJUGATE

CStone | October 29, 2020

news image

CStone Pharmaceuticals declared today a permitting concurrence with Lego Chem Bio sciences, Inc, for the turn of events and commercialization of LCB71, a likely first-in-class/top tier immunizer drug form ("ADC"). Under the understanding, CStone gets the selective worldwide option to lead advancement and commercialization of LCB71 outside the Republic of Korea. LCB will get a forthright installment of US$10 million, and up to US$353.5 million in combined achievement inst...

Read More

CORONAVIRUS DRAWS ATTENTION TO FDA OVERSIGHT OF CHINESE DRUGS

Political News - POLITICO | February 07, 2020

news image

Lawmakers are raising concerns anew about the U.S. reliance on foreign drug manufacturing amid the Wuhan coronavirus outbreak that has pushed FDA inspectors out of China. The novel disease outbreak could spark medical product shortages if the epidemic is not resolved swiftly, experts say. The challenges come as Chinese drug manufacturing has been in Congress's spotlight following a series of warnings last year about contaminated batches of foreign-made drugs. “There is emerging and I t...

Read More
news image

Business Insights

BIOMARIN ANNOUNCES ADVANCEMENTS IN FDA REVIEW OF ROCTAVIAN™ (VALOCTOCOGENE ROXAPARVOVEC) FOR ADULTS WITH SEVERE HEMOPHILIA A

BioMarin Pharmaceutical Inc. | November 24, 2022

BioMarin Pharmaceutical Inc. announced advancements in the U.S. Food and Drug Administration review of the Biologics License Application of ROCTAVIAN™ for adults with severe hemophilia A. The Company was recently notified by the FDA that after further consideration, at this time, the Agency no longer plans to hold an advisory committee meeting to discuss the BLA for ROCTAVIAN that is currently under review. Previously, the FDA communicated to the Company that it did intend to hold an...

Read More
news image

Business Insights

STALLERGENES GREER STRENGTHENS PRECISION MEDICINE APPROACH IN ALLERGEN IMMUNOTHERAPY WITH IMPERIAL COLLEGE LONDON RESEARCH COLLABORATION

Stallergenes Greer | January 17, 2022

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine. This long-term research collaboration, which combines the long-standing expertise of Stallergenes Greer in AIT with the prestigious r...

Read More
news image

Pharmacy Market

CSTONE AND LEGOCHEM BIOSCIENCES ENTER GLOBAL LICENSING AGREEMENT FOR NEW ANTIBODY DRUG CONJUGATE

CStone | October 29, 2020

CStone Pharmaceuticals declared today a permitting concurrence with Lego Chem Bio sciences, Inc, for the turn of events and commercialization of LCB71, a likely first-in-class/top tier immunizer drug form ("ADC"). Under the understanding, CStone gets the selective worldwide option to lead advancement and commercialization of LCB71 outside the Republic of Korea. LCB will get a forthright installment of US$10 million, and up to US$353.5 million in combined achievement inst...

Read More
news image

CORONAVIRUS DRAWS ATTENTION TO FDA OVERSIGHT OF CHINESE DRUGS

Political News - POLITICO | February 07, 2020

Lawmakers are raising concerns anew about the U.S. reliance on foreign drug manufacturing amid the Wuhan coronavirus outbreak that has pushed FDA inspectors out of China. The novel disease outbreak could spark medical product shortages if the epidemic is not resolved swiftly, experts say. The challenges come as Chinese drug manufacturing has been in Congress's spotlight following a series of warnings last year about contaminated batches of foreign-made drugs. “There is emerging and I t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us